EXACT Therapeutics Expands its Board of Directors following the EGM

19 Dec 2024 09:01 CET

Oslo, Norway; 19 December, 2024. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, welcomes two new board members, Vice
Chair Jonathan Allis and Director Flavien Daloz, following the extraordinary
general meeting on 17 December, 2024.

In line with the development ambitions and internationalization of the Company
over the last years and following the investment by GE Medical Holdings AB it
has been the ambition to further internationalize the Board of Directors. The
new board members, Jonathan Allis and Flavien Daloz, both bring significant
industry experience.

“As board members, Jonathan and Flavien collectively bring decades of
international pharmaceutical and med-tech industry experience to EXACT
Therapeutics,” said Anders Wold, Chair of the Board of Directors. “We will
leverage their extensive skills and expertise as EXACT Therapeutics advances its
development pipeline and matures its company strategy in the ambition to improve
the lives of cancer patients.”

Dr. Jonathan Allis is a scientist turned entrepreneur and was the founding CEO
of Blue Earth Diagnostics, a spin-out from GE Healthcare established in 2014.
Blue Earth Diagnostics developed a prostate cancer diagnostic approved by the
FDA in 2016, which became a successful product in the USA. The company was
acquired by Bracco Imaging in 2019. Jonathan also served as a Board member and
Chair of Polarean Imaging. Prior to these roles, Jonathan was the general
manager for PET at GE Healthcare Life Sciences and was responsible for GE
Healthcare’s PET agent and PET synthesis platforms business globally. He has
previously held positions in R&D, Marketing and Product Development at GE
Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet
Technology in the UK, USA and Germany. Jonathan has an undergraduate degree in
Physics from the University of Cape Town and a doctorate in Biochemistry from
the University of Oxford.

Mr. Flavien Daloz is the Chief Technology Officer for Ultrasound Probes under
the GEHC Advanced Visualization Solutions segment. In his 15+ years of
experience, Mr. Daloz has held various leadership positions in the Medical
Ultrasound industry, with a proven record in innovation and new product
introductions. He was the recipient of GEHC Edison Pioneer Award in 2021 for his
influence in medical ultrasound transducer breakthrough. Mr. Daloz holds an
engineering degree from ESPCI school in Paris and an MSc in Bioimaging sciences
from Imperial College, London. He has completed a Business Leadership Program
from Michigan Ross, US.

The full composition of the board of Directors may be found following this link:
https://exact-tx.com/board-of-directors

About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications including brain diseases. www.exact-tx.com

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site